Serum of transthyretin as a treatment-responsive biomarker for schizophrenia

Nobuaki Nakagawa, Hiroshi Yao, Tatsuo Nakahara, Shinsaku Inomata, Kijiro Hashimoto, Toshihide Kuroki

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

We investigated the changes in protein profiles of treatment responsive biomarkers in three subjects with first-onset schizophrenia using the surface enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS) technology. Our results showed that eight protein peaks were down-regulated or up-regulated during the acute phase, and returned toward the control values during the recovery phase. In particular, a 13,761Da protein peak was markedly down-regulated during the acute phase, and returned during the recovery phase. This protein was identified as unmodified transthyretin using two-dimensional electrophoresis followed by peptide mass fingerprinting based on matrix assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). However, we failed to show transthyretin changes with the treatment using enzyme-linked immunosorbent assay (ELISA) and two-dimensional electrophoresis. The distinction between unmodified and modified subtypes of transthyretin was difficult with these methods because of similar molecular weights and isoelectric points in these subtypes. The present study showed that the application of SELDI-TOF-MS technology has higher precision for the distinction of detailed molecular weight than conventional proteomics techniques such as ELISA and two-dimensional electrophoresis. The dynamic changes in transthyretin have been reported to be associated with acute-psychosis condition; the present study suggested that unmodified transthyretin has the potential to be a treatment responsive biomarker for schizophrenia.

Original languageEnglish
Pages (from-to)1093-1099
Number of pages7
JournalBrain and Nerve
Volume65
Issue number9
Publication statusPublished - Sep 1 2013

Fingerprint

Prealbumin
Schizophrenia
Biomarkers
Electrophoresis
Mass Spectrometry
Serum
Lasers
Proteins
Molecular Weight
Enzyme-Linked Immunosorbent Assay
Technology
Therapeutics
Peptide Mapping
Isoelectric Point
Psychotic Disorders
Proteomics

All Science Journal Classification (ASJC) codes

  • Clinical Neurology

Cite this

Nakagawa, N., Yao, H., Nakahara, T., Inomata, S., Hashimoto, K., & Kuroki, T. (2013). Serum of transthyretin as a treatment-responsive biomarker for schizophrenia. Brain and Nerve, 65(9), 1093-1099.

Serum of transthyretin as a treatment-responsive biomarker for schizophrenia. / Nakagawa, Nobuaki; Yao, Hiroshi; Nakahara, Tatsuo; Inomata, Shinsaku; Hashimoto, Kijiro; Kuroki, Toshihide.

In: Brain and Nerve, Vol. 65, No. 9, 01.09.2013, p. 1093-1099.

Research output: Contribution to journalArticle

Nakagawa, N, Yao, H, Nakahara, T, Inomata, S, Hashimoto, K & Kuroki, T 2013, 'Serum of transthyretin as a treatment-responsive biomarker for schizophrenia', Brain and Nerve, vol. 65, no. 9, pp. 1093-1099.
Nakagawa N, Yao H, Nakahara T, Inomata S, Hashimoto K, Kuroki T. Serum of transthyretin as a treatment-responsive biomarker for schizophrenia. Brain and Nerve. 2013 Sep 1;65(9):1093-1099.
Nakagawa, Nobuaki ; Yao, Hiroshi ; Nakahara, Tatsuo ; Inomata, Shinsaku ; Hashimoto, Kijiro ; Kuroki, Toshihide. / Serum of transthyretin as a treatment-responsive biomarker for schizophrenia. In: Brain and Nerve. 2013 ; Vol. 65, No. 9. pp. 1093-1099.
@article{2f005bc2aa8443d48956284bfa6443d0,
title = "Serum of transthyretin as a treatment-responsive biomarker for schizophrenia",
abstract = "We investigated the changes in protein profiles of treatment responsive biomarkers in three subjects with first-onset schizophrenia using the surface enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS) technology. Our results showed that eight protein peaks were down-regulated or up-regulated during the acute phase, and returned toward the control values during the recovery phase. In particular, a 13,761Da protein peak was markedly down-regulated during the acute phase, and returned during the recovery phase. This protein was identified as unmodified transthyretin using two-dimensional electrophoresis followed by peptide mass fingerprinting based on matrix assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). However, we failed to show transthyretin changes with the treatment using enzyme-linked immunosorbent assay (ELISA) and two-dimensional electrophoresis. The distinction between unmodified and modified subtypes of transthyretin was difficult with these methods because of similar molecular weights and isoelectric points in these subtypes. The present study showed that the application of SELDI-TOF-MS technology has higher precision for the distinction of detailed molecular weight than conventional proteomics techniques such as ELISA and two-dimensional electrophoresis. The dynamic changes in transthyretin have been reported to be associated with acute-psychosis condition; the present study suggested that unmodified transthyretin has the potential to be a treatment responsive biomarker for schizophrenia.",
author = "Nobuaki Nakagawa and Hiroshi Yao and Tatsuo Nakahara and Shinsaku Inomata and Kijiro Hashimoto and Toshihide Kuroki",
year = "2013",
month = "9",
day = "1",
language = "English",
volume = "65",
pages = "1093--1099",
journal = "Brain and Nerve",
issn = "1881-6096",
publisher = "Igaku-Shoin Ltd",
number = "9",

}

TY - JOUR

T1 - Serum of transthyretin as a treatment-responsive biomarker for schizophrenia

AU - Nakagawa, Nobuaki

AU - Yao, Hiroshi

AU - Nakahara, Tatsuo

AU - Inomata, Shinsaku

AU - Hashimoto, Kijiro

AU - Kuroki, Toshihide

PY - 2013/9/1

Y1 - 2013/9/1

N2 - We investigated the changes in protein profiles of treatment responsive biomarkers in three subjects with first-onset schizophrenia using the surface enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS) technology. Our results showed that eight protein peaks were down-regulated or up-regulated during the acute phase, and returned toward the control values during the recovery phase. In particular, a 13,761Da protein peak was markedly down-regulated during the acute phase, and returned during the recovery phase. This protein was identified as unmodified transthyretin using two-dimensional electrophoresis followed by peptide mass fingerprinting based on matrix assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). However, we failed to show transthyretin changes with the treatment using enzyme-linked immunosorbent assay (ELISA) and two-dimensional electrophoresis. The distinction between unmodified and modified subtypes of transthyretin was difficult with these methods because of similar molecular weights and isoelectric points in these subtypes. The present study showed that the application of SELDI-TOF-MS technology has higher precision for the distinction of detailed molecular weight than conventional proteomics techniques such as ELISA and two-dimensional electrophoresis. The dynamic changes in transthyretin have been reported to be associated with acute-psychosis condition; the present study suggested that unmodified transthyretin has the potential to be a treatment responsive biomarker for schizophrenia.

AB - We investigated the changes in protein profiles of treatment responsive biomarkers in three subjects with first-onset schizophrenia using the surface enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS) technology. Our results showed that eight protein peaks were down-regulated or up-regulated during the acute phase, and returned toward the control values during the recovery phase. In particular, a 13,761Da protein peak was markedly down-regulated during the acute phase, and returned during the recovery phase. This protein was identified as unmodified transthyretin using two-dimensional electrophoresis followed by peptide mass fingerprinting based on matrix assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). However, we failed to show transthyretin changes with the treatment using enzyme-linked immunosorbent assay (ELISA) and two-dimensional electrophoresis. The distinction between unmodified and modified subtypes of transthyretin was difficult with these methods because of similar molecular weights and isoelectric points in these subtypes. The present study showed that the application of SELDI-TOF-MS technology has higher precision for the distinction of detailed molecular weight than conventional proteomics techniques such as ELISA and two-dimensional electrophoresis. The dynamic changes in transthyretin have been reported to be associated with acute-psychosis condition; the present study suggested that unmodified transthyretin has the potential to be a treatment responsive biomarker for schizophrenia.

UR - http://www.scopus.com/inward/record.url?scp=84884303159&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884303159&partnerID=8YFLogxK

M3 - Article

C2 - 24018746

AN - SCOPUS:84884303159

VL - 65

SP - 1093

EP - 1099

JO - Brain and Nerve

JF - Brain and Nerve

SN - 1881-6096

IS - 9

ER -